DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 203634

NOTIFICATION OF NON-COMPLIANCE WITH PREA

Santarus, Inc.
Attention: Jennifer S. Knicley, M.S.
Senior Manager, US Regulatory Affairs
400 Somerset Corporate Boulevard
Bridgewater, NJ 08807

Dear Ms. Knicley:

Please refer to your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for Uceris (budesonide) 9 mg tablets, which was approved on January 14, 2013.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for PMR 1997-1, which was deferred until September 30, 2016.

Under the provisions of title V, section 505, of the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a "**DEFERRAL EXTENSION REQUESTED**" in your response. We note that you requested a deferral extension on June 9, 2016; however, we have determined that your request did not qualify for an extension.

In accordance with FDASIA, FDA will post this letter and your response on the website located at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm343203.htm with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a "**RESPONSE TO PREA NON-COMPLIANCE LETTER.**" To facilitate our review, submit this information to your NDA with a cross-reference letter to the IND to which your protocol has been submitted.

If you have any questions, call Kelly Richards, Regulatory Project Manager, at (240) 402-4276.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
10/04/2016